Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial (vol 16, pg 31, 2016)

被引：0
|
作者：
Tapia, M. D.
Sow, S. O.
Lyke, K. E.
机构：
来源：
LANCET INFECTIOUS DISEASES | 2016年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：16 / 16
页数：1
相关论文
共 50 条
  • [1] Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
    Tapia, Milagritos D.
    Sow, Samba O.
    Lyke, Kirsten E.
    Haidara, Fadima Cheick
    Diallo, Fatoumata
    Doumbia, Moussa
    Traore, Awa
    Coulibaly, Flanon
    Kodio, Mamoudou
    Onwuchekwa, Uma
    Sztein, Marcelo B.
    Wahid, Rezwanul
    Campbell, James D.
    Kieny, Marie-Paule
    Moorthy, Vasee
    Imoukhuede, Egeruan B.
    Rampling, Tommy
    Roman, Francois
    De Ryck, Iris
    Bellamy, Abbie R.
    Dally, Len
    Mbaya, Olivier Tshiani
    Ploquin, Aurelie
    Zhou, Yan
    Stanley, Daphne A.
    Bailer, Robert
    Koup, Richard A.
    Roederer, Mario
    Ledgerwood, Julie
    Hill, Adrian V. S.
    Ballou, W. Ripley
    Sullivan, Nancy
    Graham, Barney
    Levine, Myron M.
    LANCET INFECTIOUS DISEASES, 2016, 16 (01): : 31 - 42
  • [2] Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension
    Sinha, Smeeta
    Nigwekar, Sagar U.
    Brandenburg, Vincent
    Gould, Lisa J.
    Serena, Thomas E.
    Moe, Sharon M.
    Aronoff, George R.
    Chatoth, Dinesh K.
    Hymes, Jeffrey L.
    Carroll, Kevin J.
    Alperovich, Gabriela
    Keller, Laurence H.
    Perello, Joan
    Gold, Alex
    Chertow, Glenn M.
    ECLINICALMEDICINE, 2024, 75
  • [3] The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
    Huttner, Angela
    Dayer, Julie-Anne
    Yerly, Sabine
    Combescure, Christophe
    Auderset, Floriane
    Desmeules, Jules
    Eickmann, Markus
    Finekh, Axel
    Goncalves, Ana Rita
    Hooper, Jay W.
    Kaya, Gurkan
    Krahling, Verena
    Kwilas, Steve
    Lemaitre, Barbara
    Matthey, Alain
    Silvera, Peter
    Becker, Stephan
    Fast, Patricia E.
    Moorthy, Vasee
    Kieny, Marie Paule
    Kaiser, Laurent
    Siegrist, Claire-Anne
    LANCET INFECTIOUS DISEASES, 2015, 15 (10): : 1156 - 1166
  • [4] Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial
    Goldstein, Neil
    Mclean, Chelsea
    Gaddah, Auguste
    Doua, Joachim
    Keshinro, Babajide
    Bus-Jacobs, Linda
    Hendriks, Jenny
    Luhn, Kerstin
    Robinson, Cynthia
    Douoguih, Macaya
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [5] DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial
    Jones, Suzanne
    Evans, Kirsten
    McElwaine-Johnn, Hilary
    Sharpe, Michaela
    Oxford, John
    Lambkin-Williams, Rob
    Mant, Tim
    Nolan, Andrew
    Zambon, Maria
    Ellis, Joanna
    Beadle, John
    Loudon, Peter T.
    VACCINE, 2009, 27 (18) : 2506 - 2512
  • [6] Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial
    Nakajima, Atsushi
    Seki, Mitsunori
    Taniguchi, Shinya
    Ohta, Akira
    Gillberg, Per-Goran
    Mattsson, Jan P.
    Camilleri, Michael
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (08): : 537 - 547
  • [7] Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial
    Wressnigg, Nina
    Poellabauer, Eva-Maria
    Aichinger, Gerald
    Portsmouth, Daniel
    Loew-Baselli, Alexandra
    Fritsch, Sandor
    Livey, Ian
    Crowe, Brian A.
    Schwendinger, Michael
    Bruehl, Peter
    Pilz, Andreas
    Dvorak, Thomas
    Singer, Jiulia
    Firth, Clair
    Luft, Benjamin
    Schmitt, Bernhard
    Zeitlinger, Markus
    Mueller, Markus
    Kollaritsch, Herwig
    Paulke-Korinek, Maria
    Esen, Meral
    Kremsner, Peter G.
    Ehrlich, Hartmut J.
    Barrett, P. Noel
    LANCET INFECTIOUS DISEASES, 2013, 13 (08): : 680 - 689
  • [8] Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study
    Jahnmatz, Moja
    Richert, Laura
    al-Tawil, Nabil
    Storsaeter, Jann
    Colin, Celine
    Bauduin, Claire
    Thalen, Marcel
    Solovay, Ken
    Rubin, Keith
    Mielcarek, Nathalie
    Thorstensson, Rigmor
    Locht, Camille
    LANCET INFECTIOUS DISEASES, 2020, 20 (11): : 1290 - 1301
  • [9] Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a largescale, randomised, double-blind placebo-controlled, phase 3 trial.
    Patil, Prachi
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2010, 29 (05) : 213 - 213
  • [10] H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial
    Rudenko, Larisa
    Isakova-Sivak, Irina
    Naykhin, Anatoly
    Kiseleva, Irina
    Stukova, Marina
    Erofeeva, Mariana
    Korenkov, Daniil
    Matyushenko, Victoria
    Sparrow, Erin
    Kieny, Marie-Paule
    LANCET INFECTIOUS DISEASES, 2016, 16 (03): : 303 - 310
12345